Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al..
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary..
J Am Coll Cardiol, (2001), 38 pp. 2101-13
[2]
Guidelines for the diagnosis and treatment of chronic heart failure..
Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology..
Eur Heart J, (2001), 22 pp. 1527-60
[3]
Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. Guías del diagnóstico, clasificación y tratamiento de la insuficiencia cardíaca y del shock cardiogénico. Rev Esp Cardiol. 1999;52 Supl 2:1-54.
[4]
The Task Force of the Working Group on Heart Failure of the European Society of Cardiology..
The treatment of heart failure..
Eur Heart J, (1997), 18 pp. 736-53
[5]
Recommendations for exercise training in chronic heart failure patients..
Working Group on Cardiac Rehabilitation and Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology..
Eur Heart J, (2001), 22 pp. 125-35
[6]
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al, for the RALES Investigators..
The effect of spironolactone on morbidity and mortality in patients with severe heart failure..
N Engl J Med, (1999), 341 pp. 709-17
[7]
The effect of digoxin on mortality and morbidity in patients with heart failure..
The Digitalis Investigation Group (DIG)..
N Engl J Med, (1997), 336 pp. 525-33
[8]
Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al..
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone (VEST) Trial Investigators..
N Engl J Med, (1998), 339 pp. 1810-6
[9]
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al, for the PROMISE Study Research Group..
Effect of oral milrinone on mortality in severe chronic heart failure..
N Engl J Med, (1991), 325 pp. 1468-75
[10]
Follath F, Cleland J, Just H, Scholtz H, Peuhkurinen K, Harjola VP, et al..
Efficacy and safety with intravenous levosimendan in severe low-output heart failure. LIDO trial..
Circulation, (1999), 100 pp. 1-646
[11]
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23(18):1422-32.
[12]
The CONSENSUS Trial Study Group..
Effects of enalapril on mortality in severe congestive heart failure..
N Engl J Med, (1987), 316 pp. 1429-35
[13]
The SOLVD Investigators..
Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure..
N Engl J Med, (1991), 325 pp. 293-302
[14]
The SAVE Trial..
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction..
N Engl J Med, (1992), 327 pp. 669-77
[15]
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al..
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group..
Circulation, (1999), 100 pp. 2312-8
[16]
Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al..
Effect of losartan compared with captopril on mortality of patients with symptomatic heart failure. Losartan Heart Failure Survival. Study ELITE II..
Lancet, (2000), 355 pp. 1582-7
[17]
Cohn JN, Tognoni G for the Valsartán Heart Failure Trial (Val-HeFT) Investigators..
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure..
N Engl J Med, (2001), 345 pp. 1667-75
[18]
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al..
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme..
Lancet, (2003), 362 pp. 759-66
[19]
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the US carvedilol study group..
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure..
N Engl J Med, (1996), 334 pp. 1349-55
[20]
CIBIS-II Investigators and Commitees..
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial..
Lancet, (1999), 353 pp. 9-13
[21]
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF Study Group)..
Lancet, (1999), 353 pp. 2001-7
[22]
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial..
Lancet, (2001), 357 pp. 1385-90
[23]
Packer M, Coats AJ.S, Fowler MB, Katus HA, Krum H, Mohacsi P, et al, for the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) Trial..
Effect of carvedilol on survival in severe chronic heart failure..
N Engl J Med, (2001), 344 pp. 1651-8
[24]
Pooole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajola M, et al..
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial randomized controlled trial..
Lancet, (2003), 362 pp. 7-13
[25]
Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA..
Sudden death presentation in patients with advanced ventricular dysfunction..
Circulation, (1993), 88 pp. 2953-61
[26]
Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al..
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia..
N Engl J Med, (1995), 333 pp. 77-82
[27]
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al..
Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppresion Trial..
N Engl J Med, (1991), 324 pp. 781-8
[28]
Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al..
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol..
Lancet, (1996), 348 pp. 7-12
[29]
Packer M, O'Connor M, Ghali JK, Pressler MR, Carson PE, Belkin RN, et al..
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. The PRAISE Trial..
N Engl J Med, (1996), 335 pp. 1107-14
[30]
Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al..
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril..
Circulation, (1997), 96 pp. 856-63
[31]
Registro español de trasplante cardíaco..
XV informe oficial (1984-2003)..
Rev Esp Cardiol, (2004), 57 pp. 1197-204
[32]
Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, et al..
Selection and treatment of candidates for heart transplantation..
Circulation, (1995), 92 pp. 3593-612
[33]
Alonso-Pulpón L, Almenar L, Crespo-Leiro MG, Silva L, Segovia J, Manito N, et al..
Guías de actuación clínica de la Sociedad Española de Cardiología. Trasplante cardíaco y de corazón-pulmones..
Rev Esp Cardiol, (1999), 52 pp. 821-39
[34]
Mudge GH, Goldstein S, Addonizio LJ, Caplan A, Mancini D, Levine TB, et al..
24th Bethesda Conference. Task force 3: Recipient guidelines/priorization..
J Am Coll Cardiol, (1993), 22 pp. 21-31
[35]
Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, et al, for the MADIT Investigators..
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia..
N Engl J Med, (1996), 335 pp. 1933-40
[36]
AVID Investigators..
A Comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias..
N Engl J Med, (1997), 337 pp. 1576-83
[37]
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8.
[38]
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12): 877-83.
[39]
Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-53.
[40]
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al..
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points..
Eur J Heart Fail, (2001), 3 pp. 481-9
[41]
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350(21):2140-50.
